Wei Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Lu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- He Zhang
Urodynamic Centre, Henan Joint International Pediatric Urodynamic Laboratory and Department of Urology, The First Affiliated Hospital of Zhengzhou University
1 shared publication - Jian Guo Wen
Pediatric Urodynamic Center, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, China
1 shared publication - Jinjin Feng
Urodynamic Centre, Henan Joint International Pediatric Urodynamic Laboratory and Department of Urology, The First Affiliated Hospital of Zhengzhou University
1 shared publication - Lei Lyu
Department of Urology and Henan Joint International Paediatric Urodynamic Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication - Qi Li
Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
1 shared publication - Qingwei Wang
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication
Latest Publications
- Open Access
- 4 November 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (2) , 2415519
Piezo1 facilitates the initiation and progression of renal fibrosis by mediating cell apoptosis and mitochondrial dysfunction
Renal fibrosis is the major pathological changes of Chronic kidney disease (CKD). Piezo1, a mechanical sensitive ion channel, is implicated in organ fibrosis. However, the precise role of Piezo1 in CKD fibrosis is unknown. The aims of this study were to identify that the role of Piezo1 in CKD fibrosis and its potential involvement of mitochondrial dysfunction. We performed the study with the Piezo1 agonist Yoda1, Bax inhibitor BAI1, Piezo1 inhibitor GsMTx4 and detected the injury, fibrosis, apoptosis markers and mitochondrial dysfunction. The results showed that the levels of apoptosis, mitochondrial dysfunction, injury and fibrosis increased in TCMK-1 cells after treatment with Yoda1. However, these changes that induced by Yoda1 were relieved by BAI1. Similarly, inhibition Piezo1 with GsMTx4 also partly relieved the renal injury, renal fibrosis, apoptosis and mitochondrial dysfunction in vivo and vitro. In conclusion, we found Piezo1 promoted the initiation and development of renal fibrosis and inhibiting Piezo1 improved the fibrosis.
- 4 November 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (2) , 2415519
Open AccessPiezo1 facilitates the initiation and progression of renal fibrosis by mediating cell apoptosis and mitochondrial dysfunction
Renal fibrosis is the major pathological changes of Chronic kidney disease (CKD). Piezo1, a mechanical sensitive ion channel, is implicated in organ fibrosis. However, the precise role of Piezo1 in CKD fibrosis is unknown. The aims of this study were to identify that the role of Piezo1 in CKD fibrosis and its potential involvement of mitochondrial dysfunction. We performed the study with the Piezo1 agonist Yoda1, Bax inhibitor BAI1, Piezo1 inhibitor GsMTx4 and detected the injury, fibrosis, apoptosis markers and mitochondrial dysfunction. The results showed that the levels of apoptosis, mitochondrial dysfunction, injury and fibrosis increased in TCMK-1 cells after treatment with Yoda1. However, these changes that induced by Yoda1 were relieved by BAI1. Similarly, inhibition Piezo1 with GsMTx4 also partly relieved the renal injury, renal fibrosis, apoptosis and mitochondrial dysfunction in vivo and vitro. In conclusion, we found Piezo1 promoted the initiation and development of renal fibrosis and inhibiting Piezo1 improved the fibrosis.